Clinilabs

Neurological conditions are now the leading cause of illness and disability worldwide, affecting roughly 1 in 3 people at some point in their lives. This World Brain Day, we're reminded that protecting the brain is a lifelong pursuit, and that the treatments shaping tomorrow's care are being studied today. We're proud to support the sponsors, investigators, and patients working to move neurological care forward, because better brain health for all ages starts with better science. See how we support CNS development: https://lnkd.in/gSwbbhQn  #WorldBrainDay #BrainHealthForAllAges #CNSResearch #Neuroscience #ClinicalTrials #DrugDevelopment #ClinicalResearch #Neurology #TheCROforCNS

Most people think bipolar disorder is all about mania—but that’s just myth. What other misconceptions could be clouding your bipolar trial’s data? Our infographic busts five of the most common bipolar myths and shows why accurate understanding is the foundation of successful trials. Take a look: https://lnkd.in/ginGC3Ww #BipolarDisorder #CNSResearch #ClinicalTrials #Psychiatry #DrugDevelopment #ClinicalResearch #MoodDisorders #Psychopharmacology #TheCROforCNS

CNS is all we do. With 25+ years of experience, 800+ CNS trials completed, and global expertise across psychiatry, neurology, sleep, substance use, and rare disorders, we help sponsors navigate complexity and move therapies forward with confidence. Take the first step on your pathway to CNS approval: https://lnkd.in/gbjQQjkJ  #CNSResearch #ClinicalTrials #DrugDevelopment #ClinicalResearch #Neuroscience #CRO #Biotech #Pharma #TheCROforCNS

This piece reinforces what we’ve been saying all along: In CNS, operational architecture is what determines whether a safety signal gets caught or missed.  As CNS gene therapies move from single-center proof-of-concept to multicenter trials, they generate safety data that standard eClinical monitoring frameworks weren't built to detect.  The challenges are distinctly CNS:  • Direct intracerebral delivery means neurological adverse events present differently across sites, depending on surgical experience, imaging capability, and post-op monitoring intervals  • Standard RBM platforms (calibrated for oncology or metabolic disease) carry risk thresholds and escalation workflows tuned to the wrong safety phenotype  • Validated motor instruments like the MDS-UPDRS were designed for chronic drug treatment, not the overlapping effects of surgical trauma, immune response, and transgene expression in the first 90 days post-injection  • AAV follow-up expectations stretch 2–5 years, demanding longitudinal monitoring long after the surgical team has moved on So, we'll put the author's implied question to this community: As CNS gene therapy scales, who should own solving the monitoring gap, sponsors, CROs, or eClinical vendors?  Share your thoughts in the comments!   https://lnkd.in/gwep94aY  #CNSResearch #GeneTherapy #ParkinsonsDisease #ClinicalTrials #ClinicalOperations #DrugDevelopment #Neuroscience #ClinicalResearch #TheCROforCNS

Advancing Alzheimer's disease research is one of our passions. Let’s connect at Alzheimer's Association® AAIC 2026 to discuss how our operational rigor can help you overcome the complex eligibility criteria, biomarker integration, and imaging-intensive protocols that define modern AD trials. Schedule a meeting now: https://lnkd.in/gXtrCezf #AAIC2026 #AlzheimersResearch #ClinicalTrials #CNSResearch #DrugDevelopment #ClinicalResearch #Neuroscience #DementiaResearch #TheCROforCNS

We measure drug concentrations to the nanogram, yet we still have trouble knowing if patients are actually taking their medication. In this blog, Clinilabs founder Dr. Gary Zammit examines why traditional monitoring falls short and how technology—like ingestible sensors and AI-powered dosing verification—can turn adherence into objective, auditable data. Read it now: https://lnkd.in/g3Jca9bR  #ClinicalTrials #CNSResearch #MedicationAdherence #DrugDevelopment #ClinicalResearch #ClinicalOperations #DataQuality #Neuroscience #TheCROforCNS

As the nation marks 250 years, we’re grateful to be part of work that helps shape a healthier future. Wishing everyone a fun and safe Fourth of July. #USA250 #IndependenceDay #Clinilabs

For sponsors navigating subjective endpoints and heterogeneous patient populations, getting placebo response mitigation right can make the difference between a clear result and an inconclusive one.  In this fireside chat, Dr. Gary Zammit and Dr. Stephen J. Peroutka, M.D., Ph.D unpack the science and strategy behind managing placebo effects, including:  • Why placebo response is especially pronounced in CNS trials  • How expectation and trial design can amplify or mitigate it  • Practical approaches to reduce placebo-driven noise and protect signal detection Get the tips now: https://lnkd.in/gwe_uzmX  #ClinicalTrials #CNSResearch #PlaceboResponse #DrugDevelopment #ClinicalResearch #Neuroscience #Psychopharmacology #TrialDesign #TheCROforCNS 

Clinilabs is Hiring! Looking for your next opportunity? Clinilabs is growing, and we’re always looking for talented, motivated individuals to join our team. If you’re passionate about advancing clinical research and making a meaningful impact, we’d love to hear from you. Explore our open roles and find the opportunity that’s right for you. 🔗 Check out our careers page: https://hubs.la/Q04kLp_n0 #Clinilabs #Hiring #Careers #JoinOurTeam #WeAreHiring #JobOpportunity #ClinicalResearch #NowHiring

What’s next for your neuropsychiatric clinical trial? Book a meeting with us at Federation of European Neuroscience Societies - FENS Forum 2026 to talk about how we combine scientific expertise with operational execution to help move innovative therapies closer to patients: https://lnkd.in/ePg3NQrm  #FENS2026 #Neuroscience #CNSResearch #ClinicalTrials #DrugDevelopment #NeurodegenerativeDisease #PrecisionMedicine #ClinicalResearch